Related Experiment Video
Updated: Mar 13, 2026
Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
Published on: September 30, 2021
Aspects of prophylactic treatment of hemophilia
1Department of Clinical Sciences Lund-Paediatrics, Lund University, Lund, Sweden ; Department of Paediatrics and Malmö Centre for Thrombosis and Haemostasis, Skåne University Hospital, Malmö, Sweden.
Insights
Start primary prophylaxis for severe hemophilia A or B in children aged 1-2 years, before the first joint bleed. Tailor treatment individually for optimal outcomes in hemophilia management.
Area of Science:
- Hematology
- Pediatric Medicine
- Pharmacology
Background:
- Severe hemophilia A and B require early intervention to prevent joint damage.
- Primary prophylaxis is the standard of care for severe hemophilia.
- Individualized treatment strategies are crucial for effective hemophilia management.
Approach:
- Review of retrospective and prospective studies on prophylactic treatment in hemophilia.
- Analysis of factors influencing inhibitor development in hemophilia A.
- Evaluation of enhanced half-life products for hemophilia treatment.
Key Points:
- Prophylactic treatment for severe hemophilia A and B should begin at 1-2 years of age, ideally before the first joint bleed.
- Treatment individualization is essential, considering dose, frequency, venous access, and bleeding phenotype.
- Enhanced half-life products improve treatment accessibility and efficacy, particularly for hemophilia B.
- Prophylaxis demonstrates benefits in adults and patients with inhibitors.
Conclusions:
- Early primary prophylaxis is critical for preventing long-term complications in severe hemophilia.
- Tailored prophylactic regimens and advanced formulations optimize patient outcomes.
- The benefits of prophylactic treatment extend to adult hemophilia patients and those with inhibitors.
Abstract:
Retrospective and prospective studies unambiguously show that prophylactic treatment of severe hemophilia A or B should be started as primary prophylaxis at 1-2 years' of age and ideally before the first joint bleed. The dose and dose frequency should be individually tailored depending on the goal of treatment, venous access and the bleeding phenotype. The circumstances during the first exposures of factor VIII concentrates in hemophilia A may have an impact on the risk of developing inhibitors. Enhanced half-life products, in particular in hemophilia B, will facilitate treatment in patients with difficult venous access but also in achieving a higher trough level. Evidence accumulate that prophylactic treatment is beneficial also in adults and in patients with inhibitors.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:29Venous Thrombosis III: Interprofessional Care
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:24Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:05Introduction to Hemostasis
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...